GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E17.67 EPS (ttm)3.58 Insider Own0.10% Shs Outstand1.25B Perf Week1.26%
Market Cap79.50B Forward P/E9.95 EPS next Y6.36 Insider Trans-1.60% Shs Float1.25B Perf Month-0.52%
Income4.51B PEG- EPS next Q1.53 Inst Own83.90% Short Float1.33% Perf Quarter3.23%
Sales27.47B P/S2.89 EPS this Y14.00% Inst Trans0.79% Short Ratio1.69 Perf Half Y-6.21%
Book/sh15.88 P/B3.98 EPS next Y-3.18% ROA6.80% Target Price69.52 Perf Year-8.77%
Cash/sh4.24 P/C14.93 EPS next 5Y-1.35% ROE22.00% 52W Range57.19 - 74.12 Perf YTD-12.86%
Dividend2.92 P/FCF12.58 EPS past 5Y-13.10% ROI16.40% 52W High-14.69% Beta0.35
Dividend %4.62% Quick Ratio1.30 Sales past 5Y-2.10% Gross Margin75.70% 52W Low10.57% ATR1.28
Employees14400 Current Ratio1.50 Sales Q/Q2.60% Oper. Margin26.30% RSI (14)58.71 Volatility1.70% 2.21%
OptionableYes Debt/Eq1.32 EPS Q/Q-98.90% Profit Margin16.40% Rel Volume0.53 Prev Close63.27
ShortableYes LT Debt/Eq1.26 EarningsApr 28 AMC Payout79.50% Avg Volume9.89M Price63.23
Recom2.40 SMA202.38% SMA503.90% SMA200-5.04% Volume1,131,390 Change-0.06%
Feb-28-22Downgrade BMO Capital Markets Outperform → Market Perform $75 → $65
Feb-02-22Reiterated Wells Fargo Equal Weight $72 → $70
Feb-02-22Reiterated Truist Hold $77 → $75
Feb-02-22Reiterated RBC Capital Mkts Outperform $87 → $85
Feb-02-22Reiterated BofA Securities Neutral $73 → $71
Feb-02-22Reiterated BMO Capital Markets Outperform $85 → $75
Jan-28-22Upgrade Argus Hold → Buy
Jan-06-22Downgrade Morgan Stanley Overweight → Equal-Weight $84 → $74
Dec-09-21Resumed Wells Fargo Equal Weight $72
Dec-06-21Initiated Goldman Neutral $80
Nov-19-21Upgrade BMO Capital Markets Market Perform → Outperform $72 → $85
Nov-19-21Resumed Piper Sandler Neutral $77
Oct-20-21Resumed Cowen Outperform
Jul-30-21Reiterated RBC Capital Mkts Outperform $81 → $84
Jul-30-21Reiterated BMO Capital Markets Market Perform $67 → $72
Apr-01-21Upgrade Bernstein Mkt Perform → Outperform $80
Mar-30-21Upgrade Redburn Neutral → Buy
Jan-19-21Upgrade Morgan Stanley Equal-Weight → Overweight $83
Jan-04-21Upgrade Guggenheim Neutral → Buy
Nov-03-20Resumed Morgan Stanley Equal-Weight $67
May-20-22 10:01AM  
May-19-22 01:30PM  
03:00AM  
May-18-22 11:41AM  
08:46AM  
May-17-22 04:30PM  
11:42AM  
11:30AM  
May-16-22 04:10PM  
May-13-22 01:44PM  
10:50AM  
10:45AM  
09:57AM  
May-12-22 04:04PM  
May-11-22 01:42PM  
01:05PM  
08:46AM  
May-08-22 07:05AM  
May-06-22 09:26AM  
May-04-22 06:48PM  
01:39PM  
May-03-22 09:30AM  
08:46AM  
May-02-22 08:30AM  
Apr-29-22 03:45PM  
01:57PM  
11:05AM  
09:26AM  
02:00AM  
Apr-28-22 05:25PM  
05:19PM  
04:43PM  
04:25PM  
04:02PM  
Apr-27-22 02:03PM  
12:44PM  
10:26AM  
08:38AM  
Apr-26-22 06:13PM  
05:59PM  
11:15AM  
09:26AM  
07:27AM  
06:15AM  
Apr-25-22 02:29PM  
02:20PM  
02:20PM  
11:49AM  
09:02AM  
Apr-24-22 06:05PM  
Apr-21-22 05:50PM  
03:01PM  
11:13AM  
Apr-20-22 11:31AM  
08:46AM  
Apr-19-22 10:57AM  
08:00AM  
Apr-18-22 09:26AM  
Apr-15-22 09:57AM  
Apr-14-22 04:05PM  
01:34PM  
Apr-13-22 05:50PM  
09:26AM  
08:14AM  
Apr-12-22 11:20AM  
08:49AM  
Apr-11-22 04:07PM  
Apr-08-22 11:32AM  
Apr-07-22 01:23PM  
11:13AM  
Apr-06-22 10:26AM  
09:46AM  
Apr-05-22 05:50PM  
05:30PM  
Apr-01-22 06:48PM  
06:01PM  
05:49PM  
10:26AM  
Mar-31-22 11:23AM  
Mar-30-22 05:50PM  
10:32AM  
Mar-28-22 11:00AM  
Mar-25-22 10:31AM  
Mar-23-22 10:53AM  
Mar-22-22 05:50PM  
10:31AM  
Mar-21-22 10:04AM  
Mar-18-22 10:34AM  
Mar-16-22 05:45PM  
Mar-15-22 10:31AM  
Mar-11-22 05:50PM  
Mar-10-22 12:27PM  
10:31AM  
08:20AM  
Mar-09-22 05:29PM  
12:54PM  
Mar-08-22 04:14PM  
10:31AM  
Mar-07-22 04:07PM  
08:30AM  
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lofton Kevin EDirectorApr 28Option Exercise25.6216,322418,25190,525Apr 29 06:43 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMar 11Sale58.243,634211,64432,576Mar 14 09:46 PM
Wilfong Diane E.SVP, Controller & CAOMar 10Option Exercise0.003,297027,516Mar 14 09:30 PM
Mercier JohannaChief Commercial OfficerMar 10Option Exercise0.006,987037,765Mar 14 09:14 PM
O'Day Daniel PatrickChairman & CEOMar 10Option Exercise0.0024,0030260,396Mar 14 09:52 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 09Sale63.891,691108,03832,576Feb 11 02:57 PM
Dickinson Andrew DChief Financial OfficerFeb 06Option Exercise0.001,817060,473Feb 08 08:25 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 06Option Exercise0.002,727035,303Feb 08 08:24 PM
Wilfong Diane E.SVP, Controller & CAOFeb 06Option Exercise0.001,864024,739Feb 08 08:22 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 01Sale68.5414,061963,68232,576Feb 02 06:37 PM
Wilfong Diane E.SVP, Controller & CAOAug 17Option Exercise68.0813,610926,53634,008Aug 18 07:32 PM
Wilfong Diane E.SVP, Controller & CAOAug 17Sale72.5013,610986,72520,398Aug 18 07:32 PM